Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test

Guardant Health, Inc.

2024-Q2 EPS reported -$1.78 revenue$345,726,000

Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).
GAAP net loss $102.6M ($0.84/share); non-GAAP net loss $58.5M ($0.48 loss).
FY2024 revenue guidance raised to $690-700M (prior $675-685M), growth 22-24%.
Shield blood test received FDA approval for first-line CRC screening; commercial launch; Medicare covers 45M beneficiaries.
Clinical tests 49,400 (+14%), biopharma tests 10,475 (+56%); cash $1.0B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.